Home > Neurology > EAN 2022 > Epilepsy > Real-world efficacy of cenobamate in focal-onset seizures

Real-world efficacy of cenobamate in focal-onset seizures

Presented By
Dr Giovanni Falcicchio & Dr Ariadna Gifreu
EAN 2022
Cenobamate has been recently approved as adjunctive treatment of uncontrolled, focal-onset seizures (FOS). Two case series shed light on the efficacy and safety of cenobamate in clinical practice. Results were positive and even in patients with superrefractory focal epilepsy, cenobamate was highly efficacious. Although in the past years there has been an increase in available anti-seizure medications, drug-resistance in epilepsy patients has not decreased. An Italian study, presented by Dr Giovanni Falcicchio (University Hospital of Bari "A. Moro", Italy), investigated cenobamate as adjunctive treatment for patients with uncontrolled FOS [1]. Included were 20 adult patients who were enrolled in an Italian Expanded Access Program (EAP) with uncontrolled FOS and no treatment alternatives. Collected were efficacy and safety data 3, 6, and 12 months after administration of cenobamate, along with plasma concentrations of concomitant anti-seizure medic...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on